盐酸阿霉素增强溶瘤腺病毒ZD55-TRAIL抑制肝癌细胞生长的研究

doi:10.13523/j.cb.20140205

中国生物工程杂志

2014, Vol. 34

Issue (2): 26-33 DOI: 10.13523/j.cb.20140205

研究报告

盐酸阿霉素增强溶瘤腺病毒ZD55-TRAIL抑制肝癌细胞生长的研究

刘涛, 韩华锋, 马步云, 杨远勤, 卓玲燕, 周立, 王毅刚

浙江理工大学生命科学学院新元医学与生物技术研究所杭州 310018

Novel Synergistic Anti-tumor Effects of DOX with Oncolytic Adenovirus ZD55-TRAIL on Hepatocellular Carcinoma Cells

LIU Tao, HAN Hua-feng, MA Bu-yun, YANG Yuan-qin, ZHUO Ling-yan, ZHOU Li, WANG Yi-gang

School of Life Sciences, Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou 310018, China

全文: PDF(1658 KB) HTML

摘要： 盐酸阿霉素（DOX）作为一种抗肿瘤抗生素，通过抑制癌细胞遗传物质的合成，对多种肿瘤均有杀伤作用，然而，其单独作用疗效有限，且加大剂量时其副作用较强。目前，携带抗癌基因的溶瘤腺病毒在肿瘤治疗中的作用日渐显现，溶瘤腺病毒ZD55-Trail联合DOX治疗肝癌的研究鲜有报道。通过MTT和结晶紫染色试验检测DOX药物处理对肝癌细胞系Bel-7404存活率的变化情况；Hoechst33342染色和流式细胞术检测肝癌细胞的凋亡；Western blot检测Trail蛋白和凋亡相关蛋白的表达；免疫荧光和流式细胞术检测凋亡相关受体表达的情况。结果显示，ZD55-Trail与DOX联合使用能够有效抑制肝癌细胞增长并诱导其凋亡，并且联合处理能增加Trail受体DR4和DR5的表达。初步探讨了DOX与ZD55-Trail两者协同诱导肝癌细胞凋亡的机制，为利用ZD55-Trail与DOX联合治疗肝癌提供依据。

关键词： ZD55-Trail; DOX; 肝癌; 凋亡

Abstract: Doxorubicin hydrochloride, an antitumor antibiotic, exhibits prominent killing effects in numerous malignant tumours by suppressing the synthesis of genetic material of carcinoma cells. Nevertheless, the therapeutic effect with single drug is limited and the side-effect is very strong when the dose was added. The oncolytic adenovirus armed with cancer suppressor gene plays an important role in cancer therapy. However, there is little report for the treatment of liver cancers with the combination of oncolytic adenovirus ZD55 armed with Trail and doxorubicin hydrochloride. MTT assay and crystal violet assay were used to determine the growth inhibition effects of various treatments in hepatoma carcinoma cell Bel-7404; and Hoechst 33342 staining and flow cytometry assay were used to evaluate the cell apoptosis; with Western blotting assay to detect the trail and apoptosis-related protein expression; with immunofluorescence method and flow cytometry assay to detect the expression of apoptosis-related receptor. The results indicate that the combination therapy of oncolytic adenovirus ZD55 armed with Trail and doxorubicin hydrochloride could more significantly inhibited tumor cell proliferation and induce cell apoptosis compared with single drug. The cooperation mechanism of the two drugs refer to the expression level of the Trail receptor DR4 and DR5 was explored. The above primarily explored the mechanism of apoptotic inducement by the synergy treatments with DOX and ZD55-Trail, which provide the basis for further combinational treatment of hepatocellular carcinoma.

Key words: ZD55-Trail DOX HCC Apoptosis

收稿日期: 2013-11-19 出版日期: 2014-02-25

ZTFLH:

Q789

基金资助: 国家自然科学基金（81272687）、国家“863”计划（2012AA020806）、浙江省自然科学基金（LZ13H160004）资助项目

通讯作者: 王毅刚 E-mail: Wangyigang43@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘涛
	韩华锋
	马步云
	杨远勤
	卓玲燕
	周立
	王毅刚

引用本文:

刘涛, 韩华锋, 马步云, 杨远勤, 卓玲燕, 周立, 王毅刚. 盐酸阿霉素增强溶瘤腺病毒ZD55-TRAIL抑制肝癌细胞生长的研究[J]. 中国生物工程杂志, 2014, 34(2): 26-33.

LIU Tao, HAN Hua-feng, MA Bu-yun, YANG Yuan-qin, ZHUO Ling-yan, ZHOU Li, WANG Yi-gang. Novel Synergistic Anti-tumor Effects of DOX with Oncolytic Adenovirus ZD55-TRAIL on Hepatocellular Carcinoma Cells. China Biotechnology, 2014, 34(2): 26-33.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20140205 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I2/26

[1] 叶胜龙. 2012年肝癌领域研究进展. 中华肝脏病杂志, 2013, 21(3): 167-169. Ye S L.Research progress in liver cancer area of 2012.Chinese Journal of Hepatology,2013,21(3):167-169.
[2] Nordenstedt H, White D L, El-Serag H B. The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42:206-214.
[3] Zhang Z L, Zou W G, Luo C X, et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res, 2003, 13(6): 481-489.
[4] Liu X Y. Targeting gene-virotherapy of cancer and its prosperity. Cell Res, 2006, 16(11): 879-886.
[5] Russell S J, Peng K W, Bell J C. Oncolytic virotherapy. Nat Biotechnol, 2012, 30(7): 658-670.
[6] Small E J, Carducci M A, Burke J M, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther, 2006, 14(1): 107-117.
[7] Freytag S O, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 2002, 62(17): 4968-4976.
[8] Quirin C, Mainka A, Hesse A, et al. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. International Journal of Cancer, 2007, 121(12): 2801-2807.
[9] Kaliberova L, Krendelchtchikova V, Harmon D, et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Therapy, 2009, 16(10): 794-805.
[10] Kangasniemi L, Parviainen S, Pisto T, et al. Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. International Journal of Cancer, 2012, 131(1):253-263.
[11] Song X, Wang H, Jia R, et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. International Journal of Molecular Sciences, 2012, 13(9): 10736-10749.
[12] Waterhouse D N, Tardi PG, Mayer L D, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf, 2001, 24(12): 903-920.
[13] Komdeur R, Meijer C, Van Zweeden M, et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. International Journal of Oncology, 2004, 25(3): 677.
[14] Gish R G, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. Journal of Clinical Oncology, 2007, 25(21): 3069-3075.
[15] Wiley S R, Schooley K, Smolak P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3(6): 673-682.
[16] Oikonomou E, Pintzas A. The TRAIL of oncogenes to apoptosis. Biofactors, 2013, 39(4): 343-354.
[17] Dai Y, Liu M, Tang W, et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer, 2009, 9(1): 392.
[18] Reeh M, Bockhorn M, Gorgens D, et al. Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer, 2013, 109(7): 1848-1858.
[19] Wang S, Ren W, Liu J, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res, 2010, 16(9): 2591-2604.
[20] Aroui S, Brahim S, Hamelin J, et al. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis, 2009, 14(11): 1352-1365.
[21] Liu X Y, Li H G, Zhang K J, et al. Strategy of cancer targeting gene-viro-therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy. Current Pharmaceutical Biotechnology, 2012, 13(9): 1761-1767.
[22] He X, Liu J, Yang C, et al. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells. Human Gene Therapy, 2010, 22(3): 283-292.

[1]	陶守松,任广明,尹荣华,杨晓明,马文兵,葛志强. 敲低去泛素化酶USP13抑制K562细胞的增殖^*[J]. 中国生物工程杂志, 2021, 41(5): 1-7.
[2]	段阳阳,张凤亭,成江,石瑾,杨娟,李海宁. SIRT2抑制对MPP⁺诱导的帕金森病细胞模型凋亡和线粒体动态平衡的影响^*[J]. 中国生物工程杂志, 2021, 41(4): 1-8.
[3]	郭利成,曹雪玮,傅龙云,王富军,赵健. 一种用于药物蛋白亲和纯化和跨膜转运的双功能标签的开发 ^*[J]. 中国生物工程杂志, 2020, 40(6): 40-52.
[4]	朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 ^*[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[5]	刘叶,潘玥,郑魏,胡晶. miR-186-5p在酒精诱导的心肌细胞中高表达并通过靶基因XIAP调控细胞凋亡水平 ^*[J]. 中国生物工程杂志, 2019, 39(5): 53-62.
[6]	汪路,杨丽媛,唐雨婷,陶瑶,雷力,敬一佩,蒋雪坷,张伶. 干扰PKM2对人白血病细胞增殖和凋亡的影响及潜在机制 ^*[J]. 中国生物工程杂志, 2019, 39(3): 13-20.
[7]	黄翔,杨杰,何佩彦,吴志慧,曾慧兰,王新宁,蒋建伟. 白花地胆草单体EM-12诱导2774-C10细胞G₁/S期阻滞及细胞凋亡的分子机制研究[J]. 中国生物工程杂志, 2018, 38(4): 17-23.
[8]	代立婷, 吴忠南, 黄翔, 杨杰, 曾慧兰, 王国才, 蒋建伟. 卤地菊乙醇提取物W40单体诱导GLC-82细胞凋亡的分子机制研究[J]. 中国生物工程杂志, 2017, 37(8): 1-7.
[9]	徐安健, 李艳萌, 李斯文, 乌姗娜, 张蓓, 黄坚. PHP14沉默对肺癌细胞凋亡的影响及其机制[J]. 中国生物工程杂志, 2017, 37(7): 12-17.
[10]	范梦恬, 陈思成, 郭杨柳, 李亚, 孙艳婷, 李汪, 施琼. 趋化因子受体CX3CR1对人肝癌细胞7721和HepG2的作用及其机制的研究[J]. 中国生物工程杂志, 2017, 37(6): 22-30.
[11]	李艳伟, 马义, 韩磊, 肖兴, 党诗莹, 文涛, 王得华, 范志勇. Fas凋亡抑制分子FAIM 1表达缺失诱发单纯性肥胖的初步研究[J]. 中国生物工程杂志, 2017, 37(6): 37-42.
[12]	白欣艳, 温丽敏, 王玉晶, 王海龙, 解军, 郭睿. ANKRD49通过上调Bcl-xL的表达抑制UV诱导GC-1细胞的凋亡[J]. 中国生物工程杂志, 2017, 37(4): 40-47.
[13]	冀君, 朱晨晨, 许鑫, 刘晓, 冷超粮, 史鸿飞, 姚伦广, 阚云超. 鸡贫血病毒凋亡素基因的可溶性融合表达及抗肿瘤活性分析[J]. 中国生物工程杂志, 2017, 37(2): 26-32.
[14]	谢琳娜,曾燕华,柯伙钊,何文胜,郑敏,林德馨. 在肝癌细胞SK-Hep1中沉默STAT3基因增强sorafenib疗效的初步研究^*[J]. 中国生物工程杂志, 2017, 37(12): 8-13.
[15]	余琳,王建华,葛良鹏. 靶向Glypican-3的肝癌免疫治疗研究进展^*[J]. 中国生物工程杂志, 2017, 37(12): 90-95.

Viewed

Full text

Abstract

Cited

Shared

Discussed